Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E40.32 EPS (ttm)1.56 Insider Own0.04% Shs Outstand2.75B Perf Week0.08%
Market Cap172.77B Forward P/E15.06 EPS next Y4.18 Insider Trans-16.70% Shs Float2.73B Perf Month-2.46%
Income4.35B PEG6.63 EPS next Q0.87 Inst Own75.80% Short Float0.62% Perf Quarter0.62%
Sales39.93B P/S4.33 EPS this Y-10.00% Inst Trans-0.05% Short Ratio1.92 Perf Half Y4.33%
Book/sh14.51 P/B4.34 EPS next Y8.58% ROA4.50% Target Price69.40 Perf Year7.06%
Cash/sh5.56 P/C11.33 EPS next 5Y6.08% ROE10.40% 52W Range57.18 - 66.80 Perf YTD6.91%
Dividend1.88 P/FCF102.17 EPS past 5Y-7.00% ROI6.40% 52W High-5.78% Beta0.82
Dividend %2.99% Quick Ratio1.30 Sales past 5Y-3.70% Gross Margin75.90% 52W Low10.07% ATR0.73
Employees68000 Current Ratio1.60 Sales Q/Q1.30% Oper. Margin13.20% RSI (14)43.83 Volatility0.78% 1.09%
OptionableYes Debt/Eq0.71 EPS Q/Q39.30% Profit Margin10.90% Rel Volume0.74 Prev Close62.62
ShortableYes LT Debt/Eq0.59 EarningsJul 28 BMO Payout117.50% Avg Volume8.91M Price62.94
Recom2.30 SMA20-1.57% SMA50-1.75% SMA2000.05% Volume6,655,095 Change0.51%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jul-20-17 03:17PM  Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging GlobeNewswire
12:55PM  FDA tentatively approves Merck's copycat of Sanofi's Lantus Reuters
07:30AM  Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA Nexvue (insulin glargine injection), a Follow-On Biologic Basal Insulin Business Wire
Jul-19-17 07:38AM  How Mercks Isentress Is Expected to Perform in 2017 Market Realist
Jul-18-17 05:05PM  Mercks Diabetes Franchise Could Generate Steady Revenues in 2017 Market Realist
03:14PM  How Merck Is Expected to Perform in 2017 Market Realist
Jul-17-17 07:03PM  Nasdaq posts 7-day win streak ahead of key earnings due this week
01:20PM  FedEx Expects Financial Hit From Cyber Hack; Here's Who Else Who Could Feel Petya's Pain
09:30AM  The Zacks Analyst Blog Highlights: Facebook, Verizon, Merck, Pepsi and HCA Healthcare Zacks
07:00AM  Merck Announces Presentations of Clinical and Real-World Data at The Alzheimers Association International Conference® Business Wire
Jul-14-17 04:42PM  AstraZeneca Pops On Report CEO Won't Jump Ship For Teva Pharma Investor's Business Daily
02:35PM  Gilead (GILD) Application for HIV Drug Validated in EU Zacks
02:07PM  AbbVie Inc (ABBV) Stock Isnt Done Charting New Highs Yet InvestorPlace
10:57AM  Pfizer Xeljanz Label Expansion Application Accepted by FDA Zacks
09:30AM  The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals Zacks
Jul-13-17 02:31PM  5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
11:03AM  Lilly Settles Patent Litigation on Cialis with Generic Firms Zacks
09:30AM  The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire Zacks
09:20AM  Major Pharma Short Sellers Become More Selective 24/7 Wall St.
08:13AM  5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings Zacks
Jul-11-17 08:27PM  HPV Infection Rates Plummet With Vaccination Forbes
09:04AM  Heres how much the 10 largest pharmaceutical companies spend on R&D Business Insider
Jul-10-17 04:22PM  These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now Motley Fool
09:08AM  A Look at Merck and Co.s Performance in 2Q17 Market Realist
Jul-09-17 09:20PM  What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers
Jul-07-17 10:52PM  [$$] SEC Lets More Companies Ignore Shareholder Proposals in 2017 The Wall Street Journal
06:10PM  Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market Zacks
09:09AM  How BMYs Opdivo Is Expected to Perform in 2017 Market Realist
08:25AM  Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook Zacks
05:00AM  ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children PR Newswire
04:43AM  ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children CNW Group
Jul-06-17 05:45PM  Merck to Hold Second-Quarter 2017 Sales and Earnings Conference Call on July 28 Business Wire
03:10PM  Stock market sinks as tech shares extend downdraft MarketWatch
09:53AM  Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies Zacks
09:35AM  15 Biggest Healthcare Companies in USA Insider Monkey
07:00AM  Merck to Present New Data from Clinical Trials Evaluating ISENTRESS® HD (raltegravir) and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017 Business Wire
02:40AM  PRESS DIGEST -Wall Street Journal - July 6 Reuters
Jul-05-17 06:25PM  FDA Suspends Certain Trials of Merck's Keytruda The Wall Street Journal
05:39PM  FDA puts hold on Merck multiple myeloma trials after deaths Reuters
04:50PM  Merck shares slip as 3 blood-cancer drug studies halted by FDA MarketWatch
04:47PM  FDA places clinical hold on Merck's combo therapy for multiple myeloma Reuters
04:30PM  Merck Provides Further Update on Three Multiple Myeloma Studies Evaluating KEYTRUDA® (pembrolizumab) in Combination with Pomalidomide or Lenalidomide Business Wire
01:44PM  Merck & Co., Inc. Value Analysis (NYSE:MRK) : July 5, 2017 Capital Cube
09:05AM  Merck & Co.s Animal Health Segments 1Q17 Revenues Market Realist
07:35AM  Mercks Immunology and Cardiovascular Franchise in 1Q17 Market Realist
Jul-04-17 10:36AM  Performance of Mercks Diabetes Drugs in 1Q17 Market Realist
09:06AM  Performance of Mercks Gardasil and Other Human Vaccines in 1Q17 Market Realist
08:58AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : July 4, 2017 Capital Cube
07:53AM  Incyte & Lilly's Olumiant Gets Marketing Approval in Japan Zacks
07:36AM  Keytrudas Developments in June 2017 Market Realist
Jul-03-17 10:37AM  How Did Keytruda Perform in 1Q17? Market Realist
09:30AM  The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva Zacks
07:38AM  Merck & Co. Reported 1% Growth in Its 1Q17 Revenues Market Realist
Jun-30-17 09:00PM  Beauty of Weakness; Uncertainty Remains: Rev Shark's Best Blog
05:36PM  Watch That Globe-Circling, Business-Crushing Malware Wreck Computers Fortune
02:20PM  [$$] Finger points at Russian state over Petya hack attack Financial Times
11:16AM  ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children PR Newswire
10:39AM  Mercks Valuation on June 28, 2017 Market Realist
09:09AM  Merck and Premier Inc. Expand Collaboration Market Realist
08:15AM  Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises Zacks
07:38AM  Mercks Anacetrapib and REVEAL Study Market Realist
Jun-29-17 12:01PM  3 Big Stock Charts for Thursday: Merck & Co., Inc. (MRK), Gilead Sciences, Inc. (GILD) and Valeant Pharmaceuticals Intl Inc (VRX) InvestorPlace
09:03AM  Merck & Co. Inc.: The Bear Case from a Bull Motley Fool
Jun-28-17 04:58PM  Why You Shouldnt Pay the Petya Ransomware Fortune
11:20AM  Petya Ransomware Attack: List of Companies Hit in Latest Hack InvestorPlace
08:39AM  Merck's CETP Inhibitor Reduces CV Risk in Phase III Study Zacks
07:20AM  Yahoo Finance Live: Market Movers - Jun 28th, 2017 Yahoo Finance Video
12:57AM  [$$] Cyberattacks Hit Major Companies Across Globe The Wall Street Journal
Jun-27-17 08:48PM  [$$] Cyberattacks Hit Major Companies Across Globe The Wall Street Journal
07:34PM  Cyber attack sweeps globe, researchers see 'WannaCry' link Reuters
07:22PM  This Ukrainian Company Is Likely Behind the Ransomware Wave Fortune
05:49PM  Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc. Motley Fool
04:03PM  [$$] Merck Cholesterol Drug Could Help Unlock Value
03:57PM  Everything to Know About Todays Worldwide Ransomware Attack Fortune
01:59PM  Merck says new type of cholesterol drug worked in big study Associated Press
12:45PM  Mondelez, other companies experiencing global computer ou... CNBC Videos
11:45AM  What to do if involved in a cyber attack: Former FBI spec... CNBC Videos
09:07AM  Pfizers Valuation as of June 22, 2017 Market Realist
09:03AM  Shocker: Merck Cholesterol Drug Yields Benefit Where Rivals Failed Forbes
08:28AM  Does Merck's Rally Have Legs?
07:25AM  Merck's cholesterol drug clears main goal in late-stage study Reuters
06:55AM  Merck Provides Update on REVEAL Outcomes Study of Anacetrapib Business Wire
Jun-26-17 10:24AM  After health care gains eight percent in one quarter CNBC Videos
08:28AM  The 3 Top Stocks for Your IRA in June Motley Fool
08:24AM  Better Buy: Merck & Co. Inc. vs. AbbVie Inc. Motley Fool
Jun-25-17 07:41AM  The FDA Has Never Approved a Drug Like This in Its 111-Year History Motley Fool
Jun-24-17 05:00PM  Could Merck and Leap Union Be the One for Keytruda?
Jun-22-17 07:58PM  US stocks close mixed as Nasdaq ekes out gains
02:03PM  Stock market climbs as health-care shares extend rally MarketWatch
02:03PM  Merck's Powerful Rally Is Coming So Back Up the Truck
10:12AM  Merck's Keytruda on a Roll: Can it Retain the Momentum? Zacks
08:48AM  Merck and Premier Inc. Expand Collaboration to Address Chronic Care and Vaccination Rates Business Wire
Jun-21-17 04:16PM  S&P closes lower after oil drops more than 2% again CNBC
03:00PM  Amgen An Undervalued Industry Leader Forbes
01:50PM  Dems Roast Trump for Leaving Medicare Out of Drug Price Order
Jun-20-17 04:15PM  Could Tesaro Overcome Clovis' Lead On Combos With Merck & Co.? Investor's Business Daily
02:25PM  Trump drug pricing order may be weeks away CNBC
08:27AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : June 20, 2017 Capital Cube
07:36AM  Regenerons Praluent May See Gradual Increase in 2017 Demand Market Realist
07:36AM  Key Updates on Eli Lillys Jardiance Market Realist
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaboration agreements with Aduro Biotech, Inc.; Premier Inc.; and Cancer Research Technology. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM